# Cencora, Inc.: overview

COR · NYSE · CIK 1140859 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/cor.md) · [Financials](/companies/cor/financials.md) · [Filings](/companies/cor/filings.md) · [Insiders](/companies/cor/insiders.md)

Latest reported revenue: [$84.75bn](/filings/0001140859-26-000034.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001140859-26-000034).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [79.1 d](/filings/0001140859-25-000131.md) | [81.5](/filings/0001140859-26-000006.md) | [75.5](/filings/0001140859-26-000020.md) | [80.7](/filings/0001140859-26-000034.md) | [83.7 d](/filings/0001140859-25-000131.md) | [85.9](/filings/0001140859-26-000006.md) | [78.4](/filings/0001140859-26-000020.md) | [84.8](/filings/0001140859-26-000034.md) |
| Gross margin | % | [3.2% d](/filings/0001140859-25-000131.md) | [3.1%](/filings/0001140859-26-000006.md) | [4.1%](/filings/0001140859-26-000020.md) | [3.6%](/filings/0001140859-26-000034.md) | [3.5% d](/filings/0001140859-25-000131.md) | [3.6%](/filings/0001140859-26-000006.md) | [4.6%](/filings/0001140859-26-000020.md) | [4.3%](/filings/0001140859-26-000034.md) |
| Operating margin | % | [0.2% d](/filings/0001140859-25-000131.md) | [0.9%](/filings/0001140859-26-000006.md) | [1.4%](/filings/0001140859-26-000020.md) | [1.1%](/filings/0001140859-26-000034.md) | [0.0% d](/filings/0001140859-25-000131.md) | [0.9%](/filings/0001140859-26-000006.md) | [1.5%](/filings/0001140859-26-000020.md) | [1.3%](/filings/0001140859-26-000034.md) |
| Net margin | % | [0.0% d](/filings/0001140859-25-000131.md) | [0.6%](/filings/0001140859-26-000006.md) | [1.0%](/filings/0001140859-26-000020.md) | [0.9%](/filings/0001140859-26-000034.md) | [(0.4%) d](/filings/0001140859-25-000131.md) | [0.7%](/filings/0001140859-26-000006.md) | [2.1%](/filings/0001140859-26-000020.md) | [0.9%](/filings/0001140859-26-000034.md) |
| Diluted EPS | $ per share | not reported | [2.50](/filings/0001140859-26-000006.md) | [3.68](/filings/0001140859-26-000020.md) | [3.52](/filings/0001140859-26-000034.md) | not reported | [2.87](/filings/0001140859-26-000006.md) | [8.40](/filings/0001140859-26-000020.md) | [3.94](/filings/0001140859-26-000034.md) |
| Free cash flow | $bn | [0.8 d](/filings/0001140859-25-000131.md) | [(2.8)](/filings/0001140859-26-000006.md) | [3.2 d](/filings/0001140859-26-000020.md) | [(0.1) d](/filings/0001140859-26-000034.md) | [2.9 d](/filings/0001140859-25-000131.md) | [(2.4)](/filings/0001140859-26-000006.md) | [1.2 d](/filings/0001140859-26-000020.md) | [2.4 d](/filings/0001140859-26-000034.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [214](/filings/0001140859-23-000197.md) | [239](/filings/0001140859-24-000177.md) | [262](/filings/0001140859-25-000131.md) | [294](/filings/0001140859-25-000131.md) | [321](/filings/0001140859-25-000131.md) |
| Gross margin | % | [3.2%](/filings/0001140859-23-000197.md) | [3.5%](/filings/0001140859-24-000177.md) | [3.4%](/filings/0001140859-25-000131.md) | [3.4%](/filings/0001140859-25-000131.md) | [3.6%](/filings/0001140859-25-000131.md) |
| Operating margin | % | [1.1%](/filings/0001140859-23-000197.md) | [1.0%](/filings/0001140859-24-000177.md) | [0.9%](/filings/0001140859-25-000131.md) | [0.7%](/filings/0001140859-25-000131.md) | [0.8%](/filings/0001140859-25-000131.md) |
| Net margin | % | [0.7%](/filings/0001140859-23-000197.md) | [0.7%](/filings/0001140859-24-000177.md) | [0.7%](/filings/0001140859-25-000131.md) | [0.5%](/filings/0001140859-25-000131.md) | [0.5%](/filings/0001140859-25-000131.md) |
| Diluted EPS | $ per share | [7.39](/filings/0001140859-23-000197.md) | [8.04](/filings/0001140859-24-000177.md) | [8.53](/filings/0001140859-25-000131.md) | [7.53](/filings/0001140859-25-000131.md) | [7.96](/filings/0001140859-25-000131.md) |
| Free cash flow | $bn | [2.2](/filings/0001140859-23-000197.md) | [2.2](/filings/0001140859-24-000177.md) | [3.5](/filings/0001140859-25-000131.md) | [3.0](/filings/0001140859-25-000131.md) | [3.2](/filings/0001140859-25-000131.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cor/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.15bn | 18,213,783 |  | Reduced −1,729,854 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.50bn | 12,378,943 |  | Added +65,484 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.72bn | 9,611,756 |  | Added +21,342 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.62bn | 9,273,983 |  | Added +83,432 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.67bn | 5,943,657 |  | Added +1,058,179 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.54bn | 5,454,888 |  | Reduced −111,156 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $1.38bn | 4,868,782 |  | Added +385,965 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $1.29bn | 4,559,761 |  | Added +11,149 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.17bn | 4,122,371 |  | Reduced −2,563,898 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.16bn | 4,086,271 |  | Reduced −445,641 |

## Recent filings

[All 2,017 filings](/companies/cor/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-21 | 11:48 ET | [8-K](/filings/0001104659-26-117576.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-117576 |
| 2026-09-25 | 12:11 ET | [8-K](/filings/0001104659-26-110624.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-110624 |
| 2026-08-14 | 20:06 ET | [8-K](/filings/0001104659-26-097096.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-097096 |
| 2026-08-12 | 16:38 ET | [8-K](/filings/0001104659-26-094676.md) | 7.01 Regulation FD disclosure | 0001104659-26-094676 |
| 2026-08-05 | 19:23 ET | [10-Q](/filings/0001140859-26-000034.md) | Quarterly report, period 2026-06-30 | 0001140859-26-000034 |
| 2026-08-05 | 10:45 ET | [8-K](/filings/0001104659-26-090691.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-090691 |
| 2026-08-05 | 10:32 ET | [8-K](/filings/0001140859-26-000032.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140859-26-000032 |
| 2026-06-15 | 21:00 ET | [8-K](/filings/0001104659-26-074102.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-074102 |
| 2026-05-29 | 21:10 ET | [8-K](/filings/0001104659-26-068357.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-068357 |
| 2026-05-06 | 18:41 ET | [10-Q](/filings/0001140859-26-000020.md) | Quarterly report, period 2026-03-31 | 0001140859-26-000020 |

## Latest annual report

[Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001140859-25-000131.md), filed Nov 25, 2025.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1140859
- Tickers: COR
- Exchange: NYSE
- SIC code: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.